Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by and welcome to Heron Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
Heron Therapeutics Inc. (HRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 26,713,503 | $53,159,871 | 0.86% | |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 8,850,000 | $17,611,500 | +17% | 0.03% |
| 3. | Velan Capital Adam Morgan | 6,986,744 | $13,903,621 | 13% | |
| 4. | D E Shaw D. E. Shaw | 4,384,677 | $8,725,507 | +14% | 0% |
| 5. | Clearline Capital Marc Majzner | 2,226,512 | $4,430,759 | +49% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.09 | 25,000 | Officer | 79,000 | 2023-11-17 | Filing | |
| $0.94 | 50,000 | Officer | 54,000 | 2023-11-16 | Filing | |
| $0.92 | 150,000 | Officer, Director | 186,496 | 2023-11-16 | Filing | |
| $0.89 | 85,000 | Officer | 85,000 | 2023-11-16 | Filing | |
| $1.37 | 2,486,744 | Director | 6,986,744 | 2023-07-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.76 | 1,504 | Officer, Director | 10,872 | 2022-05-03 | Filing | |
| $9.73 | 300 | Director | 3,200 | 2021-12-21 | Filing | |
| $9.73 | 250 | Director | 2,840 | 2021-12-21 | Filing | |
| $12.31 | 300 | Director | 3,500 | 2021-09-21 | Filing | |
| $12.30 | 250 | Director | 3,090 | 2021-09-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,338,912 | $14,176,150 | 0% | |
| 2. | 7,162,352 | $12,175,999 | 0% | |
| 3. | 6,404,795 | $10,888,151 | 0% | |
| 4. | 5,275,236 | $8,967,901 | 3.75% | |
| 5. | 3,646,103 | $6,198,375 | 0.16% |
News See All
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Jermaine, and I will be your conference operator today. At this time, I would like to welcome everyone to Heron Therapeutics Q2 2024 Conference Call.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.0209, expectations were $-0.08.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Heron Therapeutics Fourth Quarter 2023 Conference Call.
12 Best Rising Penny Stocks To Buy
Stocks are roaring after Nvidia posted yet another strong quarter, crushing AI naysayers who were calling the stock overvalued and the AI wave a hype.
Hedge Funds Say These 5 Penny Stocks are Poised to Explode
Below you can find the list of 5 penny stocks that are poised to explode according to hedge funds.
13 Hot Penny Stocks To Buy According to Hedge Funds
The overall market optimism helped by expectations that the Fed might start cutting interest rates in 2024 is helping riskier assets and equities, including small-cap stocks, penny stocks and cryptocurrencies...
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q3 2023 Earnings Conference Call. As a reminder, this conference is being recorded.
11 Best Long-Term Penny Stocks to Buy Now
The Federal Reserve’s historic battle against inflation that started in 2022 has highlighted the importance of an already-known fact: if you want to beat inflation always invest money wisely with a ...
Billionaire Hedge Funds
